Form 4: Bio-Rad Laboratories Executive Acquires Stock Options
SEC Form 4 Filing
James Barry, EVP and President of LSG at Bio-Rad Laboratories, acquired 2,918 non-qualified stock options on March 3, 2025, vesting over four years.
Summary
- James Barry, an executive at Bio-Rad Laboratories, filed a Form 4 to report changes in beneficial ownership.
- On March 3, 2025, Barry acquired 2,918 non-qualified stock options with an exercise price of $256.45.
- These options vest over four years, at a rate of 25% per year on the anniversary of the grant date.
- The options expire on March 3, 2035.
- Following the transaction, Barry directly owns 2,918 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently indicate positive or negative sentiment, but rather reports a transaction.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment with company performance.
Stakeholder Impact
- The acquisition of stock options by an executive can align their interests with those of shareholders, potentially incentivizing them to improve company performance.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of stock option acquisition |
| 03/04/2025 | Date of Form 4 signature |
| 03/03/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.